29 November 2020 : Database Analysis
Comparison of Incidence and Outcomes of Neuroblastoma in Children, Adolescents, and Adults in the United States: A Surveillance, Epidemiology, and End Results (SEER) Program Population Study
Ping Yan1AB, Feng Qi2BE, Lanzheng Bian3BC, Yajuan Xu1BD, Jing Zhou3D, Jiajie Hu3F, Lei Ren3CE, Mei Li3AG*, Weibin Tang1AFGDOI: 10.12659/MSM.927218
Med Sci Monit 2020; 26:e927218
Table 1 Characteristics of patients with neuroblastoma, stratified by age group.
Variables | Total | Children | Adolescents/adults | P value |
---|---|---|---|---|
N | 4,280 | 3,998 | 282 | |
Age, year | ||||
Median (IQR) | 1 (0–4) | 1 (0–3) | 31 (20–53) | |
Mean±SD | 4.43±10.28 | 2.15±2.735 | 36.77±19.463 | |
Sex, n (%) | 0.768 | |||
Male | 2,237 (52.27) | 2,092 (52.33) | 145 (51.42) | |
Female | 2,043 (47.73) | 1,906 (47.67) | 137 (48.58) | |
Race, n (%) | 0.172 | |||
White | 3,367 (78.67) | 3,156 (78.94) | 211 (74.82) | |
Black | 547 (12.78) | 499 (12.48) | 48 (17.02) | |
Other | 324 (7.57) | 304 (7.60) | 20 (7.09) | |
Unknown | 42 (0.98) | 39 (0.98) | 3 (1.06) | |
SEER stage, n (%) | ||||
Localized | 861 (20.12) | 787 (19.68) | 74 (26.24) | |
Regional | 999 (23.34) | 947 (23.69) | 52 (18.44) | |
Distant | 2,009 (46.94) | 1,929 (48.25) | 80 (28.37) | |
Unstaged/blank | 411 (9.60) | 335 (8.38) | 76 (26.95) | |
Treatment era, n (%) | ||||
1975–1984 | 556 (12.99) | 487 (12.18) | 69 (24.47) | |
1985–1994 | 682 (15.93) | 631 (15.78) | 51 (18.09) | |
1995–2004 | 1,338 (31.26) | 1,259 (31.49) | 79 (28.01) | |
2005–2013 | 1,704 (39.81) | 1,621 (40.55) | 83 (29.43) | |
Surgery, n (%) | 0.208 | |||
No/unknown | 1,138 (26.59) | 1,054 (26.36) | 84 (29.79) | |
Yes | 3,142 (73.41) | 2,944 (73.64) | 198 (70.21) | |
Median household income, n (%)* | 0.814 | |||
Low | 2,305 (53.87) | 2,155 (53.92) | 150 (53.19) | |
High | 1,974 (46.13) | 1,842 (46.08) | 132 (46.81) | |
Histological stage, n (%) | ||||
Neuroblastoma | 3,580 (83.64) | 3,364 (84.14) | 216 (76.60) | |
Ganglioneuroblastoma | 700 (16.36) | 634 (15.86) | 66 (23.40) | |
Place of residence, n (%) | 0.556 | |||
Urban | 3,488 (81.50) | 3,265 (81.67) | 223 (79.08) | |
Rural | 713 (16.66) | 660 (16.51) | 53 (18.79) | |
Missing/unknown | 79 (1.85) | 73 (1.83) | 6 (2.13) | |
Primary site, n (%) | ||||
Abdomen | 2,708 (63.27) | 2,610 (65.28) | 98 (34.75) | |
Mediastinum/thorax | 697 (16.29) | 674 (16.86) | 23 (8.16) | |
Nerve system | 341 (7.97) | 248 (6.20) | 93 (32.98) | |
Head and neck | 150 (3.50) | 122 (3.05) | 28 (9.93) | |
Pelvis/extremities/vertebral | 150 (3.50) | 130 (3.25) | 20 (7.09) | |
NOS, unknown | 234 (5.47) | 214 (5.35) | 20 (7.09) | |
Primary malignancies, n (%) | ||||
First primary | 4,245 (99.18) | 3,981 (99.57) | 264 (93.62) | |
1 total | 4,164 (97.29) | 3,914 (97.90) | 250 (88.65) | |
2 total | 100 (2.34) | 74 (1.85) | 26 (9.22) | |
>2 total | 16 (0.37) | 610 (0.25) | 6 (2.13) | |
Vital status, n (%) | ||||
Alive | 2,840 (66.36) | 2,754 (68.88) | 86 (30.50) | |
Dead | 1,440 (33.64) | 1,244 (31.12) | 196 (69.50) | |
IQR – interquartile range, SD – standard deviation, SEER – Surveillance, Epidemiology and End Results. * One patient was excluded because of the unknown median household income. |